This transaction is the third acquisition by three different Japanese players in this segment
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
The academy has secured partnerships with 15 esteemed hospitals
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Ibara will drive AI-powered clinical research innovation
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Subscribe To Our Newsletter & Stay Updated
